MS-DRG 16 – Autologous Bone Marrow Transplant with CC/MCC
A Medical DRG in Pre-MDC (Pre-MDC). Its FY 2027 relative weight is 6.0136 with a geometric mean length of stay of 15.6 days.
Severity family
The grouper first assigns the case to Pre-MDC from the principal diagnosis and finds no qualifying operating-room procedure (this is a Medical DRG; ICD-10-PCS codes do not drive assignment here), then applies the severity split from secondary diagnoses: with CC/MCC → 16; without CC/MCC → 17.
Principal Diagnosis Codes
Procedure Codes 21 codes · 4 categories
3023 Administration, Circulatory, Transfusion4 codes
- 30233C0 Transfusion of Autologous Hematopoietic Stem/Progenitor Cells, Genetically Modified into Peripheral Vein, Percutaneous Approach
- 30233G0 Transfusion of Autologous Bone Marrow into Peripheral Vein, Percutaneous Approach
- 30233X0 Transfusion of Autologous Cord Blood Stem Cells into Peripheral Vein, Percutaneous Approach
- 30233Y0 Transfusion of Autologous Hematopoietic Stem Cells into Peripheral Vein, Percutaneous Approach
3024 Administration, Circulatory, Transfusion4 codes
- 30243C0 Transfusion of Autologous Hematopoietic Stem/Progenitor Cells, Genetically Modified into Central Vein, Percutaneous Approach
- 30243G0 Transfusion of Autologous Bone Marrow into Central Vein, Percutaneous Approach
- 30243X0 Transfusion of Autologous Cord Blood Stem Cells into Central Vein, Percutaneous Approach
- 30243Y0 Transfusion of Autologous Hematopoietic Stem Cells into Central Vein, Percutaneous Approach
XW13 New Technology, Anatomical Regions, Transfusion6 codes
- XW1337A Transfusion of Marnetegragene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 10
- XW133B8 Transfusion of Betibeglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 8
- XW133G8 Transfusion of Atidarsagene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 8
- XW133H9 Transfusion of Lovotibeglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 9
- XW133J8 Transfusion of Exagamglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 8
- XW133SB Transfusion of Mozafancogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 11
XW14 New Technology, Anatomical Regions, Transfusion7 codes
- XW1437A Transfusion of Marnetegragene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 10
- XW143B8 Transfusion of Betibeglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8
- XW143F8 Transfusion of Etuvetidigene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8
- XW143G8 Transfusion of Atidarsagene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8
- XW143H9 Transfusion of Lovotibeglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 9
- XW143J8 Transfusion of Exagamglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8
- XW143SB Transfusion of Mozafancogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 11
Frequently Asked Questions
What is MS-DRG 16?
MS-DRG 16 (Autologous Bone Marrow Transplant with CC/MCC) is a medical DRG in Pre-MDC (Pre-MDC). Its FY 2027 relative weight is 6.0136 with a geometric mean length of stay of 15.6 days.
What is the difference between DRG 16, 17?
All 2 share the same base category; the severity of secondary diagnoses separates them: 16 (with CC/MCC), 17 (without CC/MCC). A major complication or comorbidity (MCC) places the case in the highest-weighted DRG of the family; a CC in the middle; neither in the lowest.
What is the relative weight of DRG 16?
The FY 2027 relative weight of this DRG is 6.0136, meaning reimbursement of roughly 6.01 times the average Medicare inpatient case. Multiply by a hospital's blended base rate for the approximate payment.
